Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
J Hepatol.
1989;9:105-113.
Benda L, Dittrich H, Ferenzi P, et al. The effectiveness of silymarin therapy on the survival rate of patients with liver cirrhosis [translated from German].
Wien Klin Wochenschr.
1980;92:678-683.
Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.
J Hepatol.
1998;28:615-621.
Horowitz JH, Rypins EB, Henderson JM, et al. Evidence for impairment of transsulfuration pathway in cirrhosis.
Gastroenterology.
1981;81:668-675.
Duce AM, Ortiz P, Cabrero C, et al. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis.
Hepatology.
1988;8:65-68.
Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
J Hepatol.
1999;30:1081-1089.
Marchesini G, Bianchi G, Rossi B, et al. Nutritional treatment with branched-chain amino acids in advanced liver cirrhosis.
J Gastroenterol.
2000;35(suppl):7-12.
Lesbere FX. Effect of endotelon on the capillary fragility index in a specific group: cirrhotic subjects [in French; English abstract].
Gaz Med Fr.
1983;90:332-337.
Liu G-T. Pharmacological actions and clinical use of
Fructus schizandrae.
Chin Med J.
1989;102:740-749.
Matsuzaki Y, Tanaka N, Osuga T. Is taurine effective for treatment of painful muscle cramps in liver cirrhosis? [letter].
Am J Gastroenterol.
1993;88:1466-1467.
Okita M, Watanabe A, Nagashima H. A vegetable protein-rich diet for the treatment of liver cirrhosis.
Acta Med Okayama.
1985;39:59-65.
Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon.
Gastroenterology. 1994;106:152-159.
Epstein O, Kato Y, Dick R, et al. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis.
Am J Clin Nutr.
1982;36:426-430.
Compston JE, Horton LW, Thompson RP. Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3.
Gut.
1979;20:133-136.
Watson JP, Jones DE, James OF, et al. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study.
J Gastroenterol Hepatol.
1999;14:1034-1040.
Lucena MI, Andrade RJ, de la Cruz JP, et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study.
Int J Clin Pharmacol Ther.
2002;40:2-8.
Lang I, et al. Hepatoprotective and immunological effects of antioxidant drugs.
Tokai J Exp Clin Med.
1990;15:123-127.
Lang I, et al. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers.
Ital J Gastroenterol.
1990;22:283-287.
Lucena MI, Andrade RJ, de la Cruz JP, et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study.
Int J Clin Pharmacol Ther.
2002;40:2-8.
Leo MA, Aleynik SI, Aleynik MK, et al. Beta-carotene beadlets potentiate hepatotoxicity of alcohol.
Am J Clin Nutr.
1997;66:1461-1469.
Ni R, Leo MA, Zhao J, Lieber CS. Toxicity of beta-carotene and its exacerbation by acetaldehyde in HepG2 cells. A
lcohol.
2001;36:281-285.
Leo MA, Lieber CS. Alcohol, vitamin A, and beta-carotene: adverse interactions, including hepatotoxicity and carcinogenicity.
Am J Clin Nutr.
1999;69:1071-1085.
Kircheis G, Wettstein M, Dahl S, et al. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.
Metab Brain Dis. 2002;17:453-462.
Mendal JN, Roy BK. Studies with Liv.52 in the treatment of infective hepatitis, chronic active hepatitis and cirrhosis of the liver.
Probe. 1983;22:217.
de Silva HA, Saparamadu PA, Thabrew MI, et al. Liv.52 in alcoholic liver disease: a prospective, controlled trial.
J Ethnopharmacol. 2003;84:47-50.
European Scientific Cooperative on Phytotherapy. Valerianae radix. Exeter, UK: ESCOP; 1996-1997:2. Monographs on the Medicinal Uses of Plant Drugs, Fascicule 4.
Chan TY, Tang CH, Critchley JA. Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian).
Postgrad Med J. 1995;71:227-228.
Chan TY. An assessment of the delayed effects associated with valerian overdose [letter].
Int J Clin Pharmacol Ther. 1998;36:569.
Avezov SA, Mansurov FKh. Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis]
Klin Med (Mosk). 2004;82:46-49,55-58.
Malaguarnera M, Pistone G, Elvira R, et al. Effects of L-carnitine in patients with hepatic encephalopathy.
World J Gastroenterol. 2006;11:7197-202.
Habu D, Shiomi S, Tamori A, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver.
JAMA. 2004;292:358-361
Huseini HF, Alavian SM, Heshmat R, et al. The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach.
Phytomedicine. 2005;12:619-624.
Prince MI, Mitchison HC, Ashley D, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial.
Aliment Pharmacol Ther. 2002;17:137-143.
Rambaldi A, Jacobs B, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.
Cochrane Database Syst Rev.
2007;CD003620.
Charlton M. Branched-chain amino Acid enriched supplements as therapy for liver disease.
J Nutr.
2005;136:295S-298S.
Kobayashi M, Ikeda K, Arase Y, et al. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus.
J Gastroenterol.
2008;43:63-70.
Saller R, Brignoli R, Melzer J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin.
Forsch Komplement Med.
2008;15:9-20.
Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl-L:-carnitine treatment in minimal hepatic encephalopathy.
Dig Dis Sci.
2008 Mar 21.
Jiang Q, Jiang XH, Zheng MH, et al. l-Ornithine-l-aspartate in the management of hepatic encephalopathy: A meta-analysis.
J Gastroenterol Hepatol.
2008 Sep 24.
McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy.
Cochrane Database Syst Rev.
2011 Nov 9;11:CD008716.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.